Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.

Momper JD, Karesh A, Green DJ, Hirsch M, Khurana M, Lee J, Kim MJ, Mulugeta Y, Sachs HC, Yao L, Burckart GJ.

J Clin Pharmacol. 2014 Nov;54(11):1239-46. doi: 10.1002/jcph.345. Epub 2014 Jun 24.

PMID:
24922179
2.

Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.

Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B.

Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review.

PMID:
24968572
3.

The newer antimuscarinic drugs: bladder control with less dry mouth.

Appell RA.

Cleve Clin J Med. 2002 Oct;69(10):761, 765-6, 768-9. Review.

PMID:
12371799
4.

Tolterodine.

Hills CJ, Winter SA, Balfour JA.

Drugs. 1998 Jun;55(6):813-20; discussion 821-2. Review.

PMID:
9617596
5.

Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.

Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP.

J Urol. 2005 Oct;174(4 Pt 2):1647-51; discussion 1651.

PMID:
16148673
6.

Advances in medical management of overactive bladder.

Richelson E, Elliott DS.

Mayo Clin Proc. 2003 Jun;78(6):681-3. No abstract available.

PMID:
12934775
8.

Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.

Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S.

J Clin Pharmacol. 2005 Aug;45(8):961-8.

PMID:
16027408
9.

[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].

Deng YJ, Ma G, Guo YF, Ge Z, Lu RG, Wang LX, Zhu HB, Chen CJ.

Zhongguo Dang Dai Er Ke Za Zhi. 2011 Jan;13(1):26-8. Chinese.

10.
11.

Detrol LA and Diropan XL for overactive bladder.

[No authors listed]

Med Lett Drugs Ther. 2001 Apr 2;43(1101):28. No abstract available.

PMID:
11283473
12.

Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.

Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI.

J Spinal Cord Med. 2004;27(3):214-8.

PMID:
15478523
13.

New perspectives on the overactive bladder: pharmacokinetics and bioavailability.

Gupta S, Sathyan G, Mori T.

Urology. 2002 Nov;60(5 Suppl 1):78-80; discussion 80-1. Review.

PMID:
12493362
14.

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D; Overactive Bladder: Judging Effective Control and Treatment Study Group.

Mayo Clin Proc. 2001 Apr;76(4):358-63.

PMID:
11322350
15.

The effects of reformulation: improved therapeutic index.

MacDiarmid S, Sandage BW Jr, Malhotra BK.

Curr Urol Rep. 2008 Nov;9(6):465-71.

PMID:
18947511
16.

Persistence with overactive bladder pharmacotherapy in a Medicaid population.

Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z.

Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9.

17.

Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.

Bolge SC, McDonnell DD, Chen A, Wan GJ.

Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review.

PMID:
17610806
18.

Tolterodine extended-release for overactive bladder.

Chung DE, Te AE.

Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review.

PMID:
19663610
19.

Editorial comment.

de Jong TP.

J Urol. 2009 Oct;182(4 Suppl):2038; discussion 2039. doi: 10.1016/j.juro.2009.05.160. Epub 2009 Aug 20. No abstract available.

PMID:
19695627
20.

Editorial comment.

Jorgensen TM.

J Urol. 2009 Oct;182(4 Suppl):2038; discussion 2039. doi: 10.1016/j.juro.2009.05.161. Epub 2009 Aug 20. No abstract available.

PMID:
19695626
Items per page

Supplemental Content

Write to the Help Desk